Premium
CAR T cells: Living HIV drugs
Author(s) -
Namdari Haideh,
Rezaei Farhad,
TeymooriRad Majid,
Mortezagholi Sahar,
Sadeghi Ahmadreza,
Akbari Abolfazl
Publication year - 2020
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.2139
Subject(s) - chimeric antigen receptor , human immunodeficiency virus (hiv) , immunology , immune system , cell therapy , medicine , virology , haematopoiesis , antiretroviral therapy , stem cell , t cell , biology , viral load , microbiology and biotechnology
Summary Human immunodeficiency virus type 1 (HIV‐1), the virus that causes AIDS (acquired immunodeficiency syndrome), is a major global public health issue. Although the advent of combined antiretroviral therapy (ART) has made significant progress in inhibiting HIV replication in patients, HIV‐infected cells remain the principal cellular reservoir of HIV, this allows HIV to rebound immediately upon stopping ART, which is considered the major obstacle to curing HIV infection. Chimeric antigen receptor (CAR) cell therapy has provided new opportunities for HIV treatment. Engineering T cells or hematopoietic stem cells (HSCs) to generate CAR T cells is a rapidly growing approach to develop an efficient immune cell to fight HIV. Herein, we review preclinical and clinical data available for the development of CAR T cells. Further, the advantages and disadvantages of clinical application of anti‐HIV CAR T cells will be discussed.